Neuroendocrine Tumors: An Evidence-Based Discussion

Neuroendocrine Tumors: An Evidence-Based Discussion

Episodes

Specialty:

All

Year:

All

EP. 1: Clinical and Biological Distinctions in Neuroendocrine Tumors

February 16th 2016

EP. 2: Disease Factors Influencing Initial Treatment Approaches in NETs

February 16th 2016

EP. 3: Determining Surgical Candidacy in NETs

February 16th 2016

EP. 4: Symptom Management in Functional NETs

February 16th 2016

EP. 5: Goals of Therapy with Somatostatin Analogs in NETs

February 16th 2016

EP. 6: The Role of Surgery in the Management of NETs

February 16th 2016

EP. 7: Anti-Angiogenesis and mTOR Inhibition in Carcinoid Tumors

February 16th 2016

EP. 8: Chemotherapy Options in Neuroendocrine Tumors

February 16th 2016

EP. 9: Peptide Receptor Radionuclide Therapy in NETs

February 16th 2016

EP. 10: Sequencing Decisions in Neuroendocrine Tumors

February 16th 2016

EP. 11: Management of Obstruction-Related Symptoms for NETs

February 16th 2016

EP. 12: Systemic Treatment Options and Sequencing in pNETs

February 16th 2016

EP. 13: The Potential for Combination Therapy in Neuroendocrine Tumors

February 16th 2016

Trending on OncLive

FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC

BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC

Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Routine Breast Imaging May Offer Little Benefit After Double Mastectomy for Early Breast Cancer